PFIZER INC Lease, Cost
PFIZER INC (PFE) reported Lease, Cost of $924.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-02-26
- PFIZER INC lease, cost for the quarter ending 2019-12-31 was $231.00M.
- PFIZER INC lease, cost for the quarter ending 2019-09-29 was $174.00M.
- PFIZER INC lease, cost for the quarter ending 2019-06-30 was $148.00M.
- PFIZER INC lease, cost for the quarter ending 2019-03-31 was $149.00M.
- PFIZER INC lease, cost for fiscal 2025 was $924.00M, a 21.50% decline from fiscal 2024.
- PFIZER INC lease, cost for fiscal 2024 was $1.18B, a 8.26% decline from fiscal 2023.
- PFIZER INC lease, cost for fiscal 2023 was $1.28B, a 5.34% increase from fiscal 2022.
- PFIZER INC lease, cost for fiscal 2022 was $1.22B, a 37.16% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month | Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $924.00M 10-K · filed 2026-02-26 | ||||
| 2024-12-31 | $1.18B 10-K · filed 2026-02-26 | ||||
| 2023-12-31 | $1.28B 10-K · filed 2026-02-26 | ||||
| 2022-12-31 | $1.22B 10-K · filed 2025-02-27 | ||||
| 2021-12-31 | $888.00M 10-K · filed 2024-02-22 | ||||
| 2020-12-31 | $772.00M 10-K · filed 2023-02-23 | $773.00M 10-K · filed 2021-02-25 | |||
| 2019-12-31 | $231.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $405.00M derived: sum of 2 quarters · filed 2022-02-24 | $553.00M derived: sum of 3 quarters · filed 2022-02-24 | $702.00M 10-K · filed 2022-02-24 | $700.00M 10-K · filed 2020-02-27 |
| 2019-09-29 | $174.00M 10-Q · filed 2019-11-07 | $322.00M derived: sum of 2 quarters · filed 2019-11-07 | $471.00M 10-Q · filed 2019-11-07 | ||
| 2019-06-30 | $148.00M 10-Q · filed 2019-08-08 | $297.00M 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $149.00M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |